Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-3150 (Esaxerenone) in Primary Aldosteronism
jRCT2080223294Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esaxerenone in primary aldosteronism (PA) and hypertension (HTN), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Change in sitting systolic blood pressure, Change in sitting diastolic blood pressure and 1 more. Started Aug 2016; status: completed.
02
Drugs
esaxerenone
03
Conditions
primary aldosteronism (PA)hypertension (HTN)
Beyond the preview
Go deeper on jRCT2080223294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223294.